Closely held CellCentric has announced that it is expanding its leadership team with the appointment of Celia Economides as Chief Financial Officer & Chief Business Officer (CFO & CBO).
According to CellCentric, this new role aligns with apivotal time for the company, following its recently announced $120M Series C financing (co-led by RA Capital Management and Forbion) and a growing body of clinical data supporting the clinical potential of inobrodib.
With more than two decades of strategic leadership experience across biotech finance, corporate development, and capital markets, Ms. Economides will oversee financial strategy, business development and investor relations as CellCentric continues to expand its global footprint. CellCentric announced the opening of its U.S. headquarters in the Boston area last month.
In a statement, Will West, CEO of CellCentric, commented, “We are thrilled to welcome Celia to CellCentric. Her proven leadership in building and financing biotech companies, coupled with her deep understanding of the U.S. market will be instrumental as we advance inobrodib towards registration. Our global footprint is expanding rapidly to meet the needs of our next phase of progress, with the goal of improving the lives of people with multiple myeloma.”
Ms. Economides remarked, “I am honored to join CellCentric at such an exciting inflection point. Inobrodibis truly a compelling potential oral first-in-class treatment for multiple myeloma. I look forward to partnering with Will, the board, our investors, and the CellCentric team to shape the next phase of growth, maximize value and ultimately bring a much-needed treatment to patients.”
